Quest Diagnostics reports Q3 2026 results
Item 2.02 Reports results
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001022079-26-000097
- Quarter ended September 30, 2026
- Exhibit 99.1 includes results
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- Under Item 2.02, it said it issued a press release that day announcing, among other things, its results for the quarter ended September 30, 2026.
- The press release is attached as Exhibit 99.1.
- The press release reports third quarter net revenues of $3,097 million, up 10.0% from $2,816 million a year earlier.
- Reported diluted EPS was $2.78, up 28.7%, and adjusted diluted EPS was $3.00, up 15.4%.
- Net income attributable to Quest Diagnostics was $312 million.
- Operating income was $479 million, or 15.5% of net revenues, and cash provided by operations was $611 million.
- Capital expenditures were $166 million.
- For the nine months ended September 30, 2026, net revenues were $9,035 million and diluted EPS was $7.86.
- The company updated its full year 2026 guidance.
- Net revenues are now expected between $12.065 billion and $12.105 billion, versus prior guidance of $11.95 billion to $12.05 billion.
- Reported diluted EPS is expected between $10.21 and $10.31, and adjusted diluted EPS between $11.25 and $11.35.
11 of 12 claims matched the filing text.
Not found in the filing text
- In its 10-Q for the quarter ended September 30, 2026, Quest Diagnostics reported revenue of $3.1 billion, net income of $312.0 million and an operating margin of 15.5%.
From the filing
Item 2.02. Results of Operations and Financial Condition
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1 Press release of Quest Diagnostics Incorporated dated October 22, 2026, announcing, among other things, its results for the quarter ended September 30, 2026.
104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
October 22, 2026
QUEST DIAGNOSTICS INCORPORATED
By: /s/ Sean D. Mersten
Sean D. Mersten
Vice President and Corporate Secretary
Quest Diagnostics Reports Third Quarter 2026 Financial Results;
Raises Revenue and EPS Guidance for Full Year 2026
SECAUCUS, N.J., October 22, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.
"We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI," said Jim Davis, Chairman, CEO and President. "Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year."
Recent Highlights:
• Announced the ability for iPhone and iPad users in the United States to conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app, available to the public later this year.
• Finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. Continued to advance our Co-Lab Solutions implementation and joint venture lab with Corewell Health in Michigan.
• Extended our AD-Detect® menu to include the FDA-cleared Roche Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test and launched a new AD-Detect test panel with pTau217, amyloid beta and APOE to help guide diagnosis and treatment decisions for Alzheimer's disease.
• Advanced Project Nova from the design phase to the solutions-build phase and continue to expect to deploy Epic solutions in our first lab in the fall of 2027.
The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange. Additional information will be provided closer to the event.
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
| Reported: | ||||||
|---|---|---|---|---|---|---|
| Net revenues3 | $3,0973 | $2,8163 | 10.0%3 | $9,0358 | $8,2298 | 9.8%8 |
| Diagnostic Information Services revenues | $3,035 | $2,755 | 10.2% | $8,845 | $8,043 | 10.0% |
| Revenue per requisition | (4.2)% | (2.8)% | ||||
| Requisition volume | 14.5% | 12.9% | ||||
| Organic requisition volume | 14.4% | 12.8% | ||||
| Operating income (a)6 | $4796 | $3866 | 24.2%6 | $1,337 | $1,170 | 14.3% |
| Operating income as a percentage of net revenues (a)6 | 15.5%6 | 13.7% | 1.8% | 14.8% | 14.2% | 0.6% |
| Net income attributable to Quest Diagnostics (a)5 | $3125 | $2455 | 27.6%5 | $884 | $747 | 18.4% |
| Diluted EPS (a)4 | $2.784 | $2.164 | 28.7%4 | $7.868 | $6.578 | 19.6%8 |
| Cash provided by operations6 | $6116 | $5636 | 8.8%6 | $1,486 | $1,421 | 4.6% |
| Capital expenditures7 | $1667 | $1447 | 15.0%7 | $418 | $369 | 13.2% |
| Adjusted (a): | ||||||
| Operating income | $517 | $458 | 13.0% | $1,466 | $1,330 | 10.3% |
| Operating income as a percentage of net revenues | 16.7% | 16.3% | 0.4% | 16.2% | 16.2% | —% |
| Net income attributable to Quest Diagnostics | $338 | $296 | 14.2% | $969 | $845 | 14.7% |
| Diluted EPS4 | $3.004 | $2.604 | 15.4%4 | $8.62 | $7.43 | 16.0% |
(a) For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.
| Updated Guidance for Full Year | 2026 | |||
|---|---|---|---|---|
| The company updates its full year 2026 guidance as follows:9 | ||||
| Updated Guidance Prior Guidance | ||||
| Low High Low High | ||||
| Net revenues $12.065 billion $12.105 billion $11.95 billion $12.05 billion10 | ||||
| Net revenues increase | 9.3% | 9.7% | 8.3% | 9.2% |
| Reported diluted EPS11 | $10.2111 | $10.3111 | $9.9711 | $10.1711 |
| Adjusted diluted EPS11 | $11.2511 | $11.3511 | $11.0511 | $11.2511 |
Cash provided by operations Approximately $1.90 billion Approximately $1.80 billion
Capital expenditures Approximately $550 million Approximately $550 million
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to comp
Similar companies
Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.
- Labcorp Holdings LH public float $21.7B, Jun 30, 2025
- Natera NTRA public float $21.8B, Jun 30, 2025
- Exact Sciences EXAS public float $10.0B, Jun 30, 2025
- Guardant Health GH public float $6.2B, Jun 30, 2025
- RadNet RDNT public float $4.1B, Jun 30, 2025